Comparative effectiveness and safety of inclisiran versus evolocumab and alirocumab: a 180-day real-world study
Abstract Background and Objectives Proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors have become an important therapeutic option for patients with dyslipidemia. Evolocumab and alirocumab are monoclonal antibodies targeting circulating PCSK9, whereas inclisiran is a small interfering R...
Gorde:
| Egile Nagusiak: | , , , , |
|---|---|
| Formatua: | Artigo |
| Hizkuntza: | Inglês |
| Argitaratua: |
BMC
2026-05-01
|
| Saila: | BMC Cardiovascular Disorders |
| Gaiak: | |
| Sarrera elektronikoa: | https://doi.org/10.1186/s12872-026-05931-5 |
| Etiketak: |
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!
|